Weiss Ratings reaffirmed their sell (d-) rating on shares of Talphera (NASDAQ:TLPH – Free Report) in a research note released on Wednesday,Weiss Ratings reports.
Talphera Trading Down 3.1%
Talphera stock opened at $1.23 on Wednesday. Talphera has a twelve month low of $0.38 and a twelve month high of $1.45. The stock has a 50 day moving average of $0.73 and a two-hundred day moving average of $0.57. The stock has a market capitalization of $56.08 million, a price-to-earnings ratio of -3.07 and a beta of 0.03.
Talphera (NASDAQ:TLPH – Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. Equities analysts predict that Talphera will post -0.64 earnings per share for the current year.
Talphera Company Profile
Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.
See Also
- Five stocks we like better than Talphera
- What is the Nasdaq? Complete Overview with History
- 3 Heavily Shorted Stocks That Could Pop on Rate Cuts
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Broadcom Gets Second $420 Target as CPO Win Boosts Outlook
- Using the MarketBeat Stock Split Calculator
- PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can
Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.
